AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AGENUS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.18+0.14 (+2.32%)
Close on Oct 19, 2026
- Market cap
- $255.47M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
99.1%+1.8 pts over 5 years
Operating margin
-17.7%+115.3 pts over 5 years
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +10.4% | +5.2% | +5.3% | +16.5% | |
| Gross profit | +9.9% | +9.0% | +5.7% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -803.7% | – | – | |
| Return on assets | -63.6% | – | – | |
| Current ratio | 2.24 | 0.88 | 0.41 | |
| Debt to equity | -3.34 | -0.10 | -0.16 | |
| Net debt to EBITDA | -0.58× | 0.73× | -4.10× | |
| Interest coverage | -5.5× | – | -0.4× | |
| Capex to revenue | 55.5% | 3.9% | 0.0% | |
| Diluted shares | 87M | 0M | 30M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Agenus generated $645.23M from operations and spent $98.02M on capital expenditure, dividends and share buybacks. 99% of that went back into the business.
Generated
$645.23M
Used
$98.02M
Capital expenditure$97.41M99%Dividends$00%Share buybacks$606.00K1%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-281.5%
×Asset turnover0.29×
×Equity multiplier-2.57×
=Return on equity, FY2017210.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2017 | -281.5% | 0.29× | -2.57× | 210.0% |
| FY2016 | -562.6% | 0.11× | 12.63× | -803.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$77.20M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$77.20M vs –
- Less leverageLong-term debt to assets fell13.5% → 0.0%
- Better liquidityCurrent ratio rose0.21 → 0.41
- No dilutionShare count did not rise21M → 30M
- Gross margin improvedGross margin up on the prior year99.53% → 99.11%
- More efficientAsset turnover rose0.33 → 0.50